Back to today’s briefing

Story perspectives

Merck KGaA Eyes SpringWorks, Shares Soar 40%!

2/11/2025

26 5

Summary

Story summary

Merck KGaA is on the brink of a significant acquisition, eyeing U.S. biotech firm SpringWorks Therapeutics, known for its innovative cancer treatments. This news sent SpringWorks' shares soaring by nearly 40%, as a deal could soon bolster Merck's oncology portfolio, especially in light of recent hurdles in drug development.

History

Historical Context

Merck KGaA's potential acquisition of SpringWorks Therapeutics mirrors AbbVie's $21 billion purchase of Pharmacyclics in 2015. Both moves aimed to enhance oncology portfolios amid challenging drug development landscapes. Historical mergers highlight the industry's trend of consolidation for innovation and market strength, shaping today's competitive biotech environment.

1 of 2

Story summary

Merck KGaA is on the brink of a significant acquisition, eyeing U.S. biotech firm SpringWorks Therapeutics, known for its innovative cancer treatments. This news sent SpringWorks' shares soaring by nearly 40%, as a deal could soon bolster Merck's oncology portfolio, especially in light of recent hurdles in drug development.

1 / 2